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Abstract
Glucocorticoids are widely used for the suppression of inflammation, but evidence
is growing that they can have rapid, non-genomic actions that have been unappreciated. Diverse cell signaling effects have been reported for glucocorticoids, leading us
to hypothesize that glucocorticoids alone can swiftly increase the 3′,5′-cyclic adenosine monophosphate (cAMP) production. We found that prednisone, fluticasone,
budesonide, and progesterone each increased cAMP levels within 3 minutes without phosphodiesterase inhibitors by measuring real-time cAMP dynamics using the
cAMP difference detector in situ assay in a variety of immortalized cell lines and primary human airway smooth muscle (HASM) cells. A membrane- impermeable glucocorticoid showed similarly rapid stimulation of cAMP, implying that responses are
initiated at the cell surface. siRNA knockdown of Gαs virtually eliminated glucocorticoidstimulated cAMP responses, suggesting that these drugs activate the cAMP production
via a G protein-coupled receptor. Estradiol had small effects on cAMP levels but G protein
estrogen receptor antagonists had little effect on responses to any of the glucocorticoids
tested. The genomic and non-genomic actions of budesonide were analyzed by RNA-Seq
analysis of 24 hours treated HASM, with and without knockdown of Gαs. A 140-gene
budesonide signature was identified, of which 48 genes represent a non-genomic signature that requires Gαs signaling. Collectively, this non-genomic cAMP signaling modality
contributes to one-third of the gene expression changes induced by glucocorticoid treatment and shifts the view of how this important class of drugs exerts its effects.
KEYWORDS
airway smooth muscle, corticosteroids, G protein-coupled receptors, membrane glucocorticoid receptor,
RNA sequencing
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IN TRO D U C T ION

Glucocorticoids are used in the treatment of a wide array of diseases, including rheumatoid arthritis, autoimmune disorders,
allergy, cancer, and respiratory syndromes. The occurrence of
side effects and glucocorticoid resistance, particularly with
systemic use, greatly hamper their use.1 The combination of
glucocorticoids ß-agonists has long been considered the most
effective means for controlling asthma and chronic obstructive pulmonary disease, even more than using either alone.2-5
While the mechanisms underlying glucocorticoid genomic
effects on enhancing the clinical efficacy of ß-agonist have
been previously studied,6 the possibility that non-genomic
signaling by glucocorticoids enhance the clinical efficacy of
ß-agonists has not been investigated due to the limited tools
to measure real time kinetics of intracellular changes in 3′,5′cyclic adenosine monophosphate (cAMP) concentration.
Conventional thought suggests that glucocorticoids alter
the cell function through changes in the gene expression that
occur via activation of ubiquitously expressed intracellular glucocorticoid receptors (GR).7 In the absence of glucocorticoid,
the GR resides in the cytoplasm then translocates to the cell
nucleus upon binding of ligand. Nuclear GR then interacts with
glucocorticoid response elements (GREs) to alter the gene expression. Various reports, some published over 25 years ago,
suggest that glucocorticoids also induce rapid alterations in
various signaling processes that appear to be non-genomic in
nature.5,8,9 The human skin blanching assay (often called the
vasoconstrictor assay) has been used for nearly 50 years as a
means of qualitatively assessing the topical availability and
potency of glucocorticoids.10 This test characterizes the potency of glucocorticoids through non-genomic effects on vasoconstriction. Some of these non-genomic effects may require
specific interactions with membrane-bound versions of GR
(mGR) or other undefined membrane components.5 Short duration treatment of various cell types with glucocorticoid affect
many different signaling events, including agonist-induced calcium release, reactive oxygen species, and arachidonic acid release.11-16 BSA-conjugated cortisol, a steroid unable to cross the
cell membrane, has been used as a tool to differentiate plasma
membrane GR effects from those of the cytosolic GR. For instance, the effects of short (5 to 90 minutes) exposure of BSAcortisol on leukemia cells was studied using proteomic tools
and 128 unique proteins were found to be specifically upregulated.17 Interestingly, the putative mGR may interact with the
NMDA receptor or may directly activate a G protein-coupled
receptor (GPCR) coupled to Gαs and/or Gq/11.18 While these and
other studies support the idea that glucocorticoids possess the
ability to modulate rapid, non-genomic signaling, none reveal
the specific signaling pathways or receptor(s) responsible.
Our studies demonstrate that glucocorticoids rapidly increase the cAMP levels in a variety of cell types. In human
airway smooth muscle (HASM) glucocorticoids trigger this

non-genomic signaling via binding to an extracellular site and
activating the stimulatory G protein, Gαs. While a GPCR might
be involved, our data suggest that the G protein estrogen receptor
(GPER) does not mediate this response. Removal of this rapid,
non-genomic signal via siRNA knockdown of Gαs modifies the
transcriptomic response to the glucocorticoid, budesonide. Out
of a 140 gene budesonide signature, the alteration of 48 of these
genes was dependent upon the Gαs-cAMP signal. Thus, of all
the canonical changes in gene transcription by glucocorticoid,
a full one-third of them require this rapid, non-genomic signal.
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Materials

Forskolin (Fsk) was purchased from LC Laboratories. Cell
culture media and components were purchased from Thermo
Fisher. Fetal bovine serum was purchased from Atlanta
Biologicals. siRNA construct for silencing GNAS were
obtained from Dharmacon. The sense sequence used was
CGAUGUGACUGCCAUCAUCUU. Secondary antibodies were obtained from Santa Cruz Biotechnology. All other
drugs and chemicals were purchased from Sigma-Aldrich unless otherwise noted.
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Cell culture

HASM cells were isolated from deceased, de-identified lung donors by enzymatic dissociation in accordance with Institutional
Review Board approval and as described previously.19 HASM
cells were grown in Ham's F-12 media (Thermo Fisher
Scientific) supplemented with 10% fetal bovine serum, pen/
strep, 25 mM HEPES, 1.7 mM CaCl2, and l-glutamine. Cells
were kept at 5% CO2 and 37°C. Experiments were performed
on cells from passage 3-7 using cells from 10 different donors
in total, and at least three different donors for each study. Patient
demographics are described in Table 1. Human fetal lung
(HFL-1) fibroblasts (American Type Culture Collection) were
grown in Ham's F12 medium with 10% fetal bovine serum and
1% antibiotic-antimycotic solution. HEK-293 cells (American
Type Culture Collection) were cultured in Dulbecco's modified
Eagle's medium (Thermo Fisher Scientific) supplemented with
10% fetal bovine serum. All cells were kept in a humidified
incubator with 5% CO2 at 37°C.
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Transfection

To transfect HASM cells with siRNA, 250 000 cells were
incubated with 100 nM siRNA (target or scrambled) for
30 minutes at room temperature using HiPerFect transfection
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TABLE 1
Designation

HASM cell patient demographics
Age

Sex

Race

N100217

39

M

Black

N041717

19

M

Caucasian

N021014

54

M

Caucasian

N101317K

54

F

Hispanic

N012317

29

F

Caucasian

N012414

20

F

Black

N030116

69

M

Caucasian

N062017

47

M

Hispanic

N080817

23

M

Black

N012518K

18

M

Caucasian

N112017K

53

M

Asian

N011118K

14

M

Caucasian

Notes: HASM cells were derived from the following patients who had no history
of asthma or chronic illness. RNA-seq analysis was performed using the cell
lines from the first six rows.

reagent (Qiagen) following the manufacturer's instructions.
Cells were then transferred to 6-well plates. After 5 hours
incubation at 37°C with 5% CO2, HASM growth media containing 5% fetal bovine serum was added for 48 hours. Media
was replaced with serum-free media for 24 hours prior to
drug treatment or assay.
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cADDis cAMP assays

We performed kinetic measurements of cAMP production in
live cells using the green cAMP difference detector in situ
(cADDis) cAMP sensor (Montana Molecular, Bozeman,
MT) as described previously.20 Briefly, sub-confluent
HASM, HFL-1, or HEK-293 cells were plated on a blackwalled, clear flat bottom 96-well plates along with recombinant BacMam virus expressing the cADDis sensor and 1 µM
trichostatin-A. Cells were grown overnight at 5% CO2 and
37°C. Media was aspirated and replaced with 180 µL per
well of 1X Dulbecco's Phosphate Buffered Saline Solution
without calcium and magnesium. The 96-well plate was covered with aluminum foil and incubated at room temperature
for 30 minutes. Cell fluorescence was read from the plate
bottom using excitation/emission wavelengths of 494 and
522 nm, respectively, using a SpectraMax M5 plate reader
(Molecular Devices). A 5 minutes kinetic read on unstimulated cells was monitored until the variability in each well's
fluorescence was ≤5%. Cells were then stimulated with the
indicated drug and fluorescence changes in each well were
read at 30 seconds intervals for 30 minutes. Data were transformed to the change in fluorescence over the initial fluorescence (ΔF/F0) then plotted and fit to a single site decay
model using GraphPad Prism 8.0 (GraphPad Software). The

|
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K value (slope) and the plateau from this one-site decay fit
are reported. To create a concentration-response curve, the K
was multiplied by the plateau for each drug concentration and
plotted on a log scale.
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Immunoblot analysis

Whole cell lysates were obtained by scraping cells in modified RIPA lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 1% Igepal CA-630, plus mammalian protease inhibitor cocktail). Whole cell lysates were separated on 10% SDSpolyacrylamide gels by electrophoresis before being transferred
to PVDF membranes (Millipore) by electroblotting. ß-actin
(Santa Cruz Biotechnology sc-47778, 1:1000 dilution) and Gαs
(Santa Cruz Biotechnology sc-135914, 1:500 dilution) antibodies were simultaneously incubated overnight at 4°C following
block in nonfat milk. The appropriate secondary antibodies
with conjugated horseradish peroxidase were purchased from
Santa Cruz Biotechnology. Images were captured using a
BioRad Gel Doc system then the alignment, exposure, and
contrast of each image was optimized using Adobe Photoshop
CS4. Immunoreactive bands were analyzed by densitometric
analysis using the volume plus density method and normalized
to ß-actin, as described previously.21
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RNA-Seq

Control or Gαs-knockdown HASM cells (see transfection
procedure above) from six different donors (see Table 1) at
the same passage number were treated with either vehicle
or 1 µM budesonide for 24 hours. Total RNA was extracted
using the miRNAeasy mini kit (Qiagen). Approximately
1 µg of RNA from each sample was used to generate RNASeq cDNA libraries for sequencing using the TruSeq RNA
Sample Prep Kit v2 (Illumina, Inc). Sequencing of 100 bp
single-end reads was performed with an Illumina HiSeq 4000
instrument at the University of California, Irvine Genomics
High-Throughput Facility.
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Data analysis and statistics

1. Data analysis and statistics: Standard curves were fit
and unknown values were extrapolated using GraphPad
Prism 8.0. Data were presented as the mean ± SEM.
Statistical comparisons (t tests and one-way analysis of
variance) were performed and graphics were generated
using GraphPad Prism 8.0.
2. RNA-Seq alignment and quantification: RNA-Seq data
quality was checked using FastQC and all samples had
high quality score (Phred score >28) for all nucleotides
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sequenced. FastQC analysis showed Illumina TrueSeq
adapters were overrepresented in two samples. Cutadapt
software was used to remove the identified adapters and
reads were filtered for a minimum length of 20 bp. The
Rsubread R package (version v1.30.6; Liao et al22) was
used to align the reads and to produce the gene-level
summarized values using hg38 annotation from the
Rsubread package. Integer-based gene counts were generated using the featureCounts function in the Rsubread
package.22,23 limma24 and edgeR (version v3.22.3) 25,26 )
packages were used to calculate FPKM values27 and a custom script to convert FPKM to TPM values.28 Ensembl
Genome Reference Consortium Human Build 38 patch
12 (GRCh38.p12) database was used to convert gene IDs
to Hugo Gene Nomenclature Commitee (HGNC) HCNC
gene symbols.29 RNA-Seq data was available in GEO
under accession number GSE130715. GSE94335, an independent dataset including 34 samples from fatal-asthma
and non-asthma donors treated with control and budesonide,40 was also processed with the same alignment and
quantification pipeline to minimize technical and analytical bias.
3. Differential gene expression and pathway analysis: Genes
with less than 100 counts in 50% of our samples were filtered
out prior to any analysis. Principal Component Analysis
(PCA) was used to investigate interpatient variability compared to treatment-specific variability. The prcromp function from the stats R package was used to compute PCAs.
Plotting of first two PCAs showed intended treatment-specific variability was more dominant than interpatient variability. Therefore, no adjustment was necessary.
4. DESeq2 R package was used to generate differential gene-lists between various treatment conditions:
(a) vehicle-treated and Gαs-knockdown vehicle-treated
HASM cells, (b) budesonide-treated and Gαs-knockdown
budesonide-treated HASM cells, (c) vehicle-treated and
budesonide-treated HASM cells, and (d) Gαs-knockdown
vehicle-treated and Gαs-knockdown budesonide-treated
HASM cells. Gene-lists from (a) and (b) were used for
in silico validation of Gαs (GNAS gene) knockdown.
Differential gene-lists from (c) and (d) represent the budesonide induced transcriptional activity in control (genomic
+ non-genomic) and Gαs-knockdown (genomic only)
HASM cells, respectively. (c) and (d) were compared to
previously published budesonide-associated differentially expressed genes by Himes et al30 for validation of
our budesonide signature (Figure S1). Overlap analysis
of signature gene-lists was performed using a Venn diagram. Then, ASSIGN, a pathway profiling toolkit, was
used to evaluate the gene-lists (c) and (d) in predicting
budesonide-induced transcriptional activity in HASM.31
(c) and (d) gene-lists were budesonide signatures due to
Gαs-independent and -dependent transcriptional changes
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due to 24-hour post-budesonide treatment, respectively.
An independent HASM dataset, GSE94335,40 was used
to validate both budesonide signatures. Predicted budesonide activity was correlated using Pearson’s correlation
to evaluate budesonide and budesonide-Gαs knockdown
signatures.
5. Gene set enrichment analysis: Using fgsea function, a
gene set enrichment analyses were performed against
KEGG molecular pathways and gene ontology gene annotations for both budesonide signatures. Cutoff values of
P < .05 and a false discovery rate (FDR) < 0.05 were used
to assess significant enrichment.
6. Analysis of budesonide transcriptional activity in publicly
available data: Connectivity scores (CSs) were assessed
using the gene-list that was unique to differentially expressed gene- list (3) using a ConnectivityMap (CMAP)
query to identify most similar and dissimilar perturbagen
signatures in a publicly available database.32
All RNA-Seq data analyses except the CMAP query were
performed in R version 3.6.0 and Bioconductor version 3.733
(R Core Team, 2014; http://www.R-project.org/). All codes
are available at https://github.com/mumtahena/gluc_HASMs.
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RESULTS

3.1 | Rapid effect of glucocorticoids on
cellular production of cAMP
Since glucocorticoids have been found to rapidly activate
different signaling pathways in neurons,9,18 we hypothesized
that glucocorticoids stimulate the cAMP production in mammalian cells. Using a highly sensitive cAMP biosensor capable of displaying rapid cAMP kinetics in live HEK-293
cells (cADDis, Montana Molecular), we examined responses
to two commonly prescribed glucocorticoids. As shown
in Figure 1A, the addition of 10 µM fluticasone increased
cAMP levels (reflected as a decay in cADDis fluorescence)
within 30-60 seconds of drug exposure. This cAMP response
reached a plateau at approximately 12 minutes and the maximal effect was nearly as efficacious as the response to a maximal concentration of the direct adenylyl cyclase activator, Fsk
(10 µM, Figure 1A). A 10-fold lower concentration of fluticasone (1 µM) also stimulated the cAMP levels, but at a somewhat slower rate of decay and smaller plateau. Fluticasone
concentrations lower than 1 µM induced responses that were
not statistically significant when compared to vehicle control
(0.1 µM fluticasone is shown). The addition of budesonide
(0.1, 1, or 10 µM) elicited responses similar to fluticasone
(Figure 1B). We also expressed the cADDis sensor in HFL-1
cells, a human fetal lung fibroblast cell line, and measured
cAMP responses to glucocorticoids. Both budesonide and

NUÑEZ et al.
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F I G U R E 1 Glucocorticoids stimulate
rapid cAMP responses in HEK-293 cells.
Cells were incubated with recombinant
BacMam virus expressing the cADDis
cAMP sensor. After establishing baseline,
fluorescence decay was monitored for
30 minutes after addition of drug. cADDis
sensor fluorescent decay curves elicited
by 1 or 10 µM fluticasone (A) 1 or 10 µM
budesonide (B) are shown. Fluorescence
decay curves elicited by vehicle and 10 µM
forskolin are shown as reference to the
minimal and maximal responses. Each
point represents the mean ± SEM of n = 5
experiments and lines represent the fit by
one-phase decay non-linear regression
analysis. * denotes P < .05 for the 1 µM
glucocorticoid conditions at the indicated
time points, # denotes P < .05 for the 10 µM
glucocorticoid conditions at the indicated
time points compared to vehicle using
multiple t tests and the Holm-Sidak method
for correction of multiple comparisons. The
0.1 µM glucocorticoid conditions were not
significantly different than vehicle

fluticasone induced rapid increases in cAMP levels in HFL-1
cells that were similar to that seen in HEK-293 cells (10 µM
budesonide plateau was −0.251 in HFL-1 cells compared to
−0.395 in HEK-293 cells; 10 µM fluticasone plateau was
−0.341 in HFL-1 cells compared −0.457 in HEK-293 cells).
Thus, two different glucocorticoids induce rapid increases in
cAMP levels in two different cell lines (HEK-293 and HFL-1
cells) and these responses were large enough to observe without the presence of phosphodiesterase (PDE) inhibitors.
When primary cultured HASM cells obtained from several donors were treated with various glucocorticoids, a rapid
production of cAMP was again observed. Prednisone (Figure
2A), fluticasone (Figure 2C), and budesonide (Figure 2D)
elicited cAMP responses in HASM within minutes of drug
addition. Prednisone induced smaller responses than fluticasone or budesonide, but significantly increased cAMP within
8 minutes of treatment. We also examined other steroids and

found that progesterone (Figure 2B) stimulated the cAMP
production in HASM cells. Estradiol did not stimulate the
cAMP responses that were significantly different than vehicle (Figure 4A). To determine if glucocorticoids increase
cAMP via inhibition of PDEs, we preincubated HASM with a
broad-spectrum PDE inhibitor, 3-isobutyl-1-methylxanthine
(IBMX). Fluticasone retained cAMP stimulating activity in
the presence of 10 µM IBMX (Figure 2E). IBMX stimulated
cADDis responses on its own, so once the baseline was set
following IBMX addition, the maximal response to Fsk was
diminished as compared to control (shown in Figure 2C). All
these responses occurred within minutes of drug addition, indicating a non-genomic mode of action.
We have recently observed that this non-genomic action
of glucocorticoids in HASM is blocked by RU486 but not
altered by knockdown of GRα.34 Therefore, we posited that
this rapid stimulation of cAMP levels involves glucocorticoid

6
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F I G U R E 2 Glucocorticoids stimulate rapid cAMP responses in HASM. Primary HASM cells were incubated with recombinant BacMam
virus expressing the cADDis cAMP sensor. After establishing baseline, fluorescence decay was monitored for 30 minutes after addition of drug.
cADDis sensor fluorescent decay curves elicited by 1 or 10 µM prednisone (A), 1 or 10 µM progesterone (B), 1 or 10 µM fluticasone (C), 1 or
10 µM budesonide (D), and 1 or 10 µM fluticasone in cell preincubated with 10 µM IBMX (E). Fluorescence decay curves elicited by 10 µM
forskolin are shown in each panel as reference to the maximal response. Fluorescence decay by cADDis was monitored for 30 minutes after
addition of either vehicle, 1 µM forskolin, 10 µM cortisol, or 10 µM cortisol-BSA (F). A different Y axis scale is used on panel E to better visualize
these responses. Each point represents the mean ± SEM of n = 4-6 donors and lines represent the fit by one-phase decay non-linear regression
analysis. * denotes P < .05, ** denotes P < .01 of each time point compared to vehicle using multiple t tests and the Holm-Sidak method for
correction of multiple comparisons

binding to a plasma membrane receptor. Addition of 10 µM
cortisol or 10 µM cortisol-BSA conjugate (the latter drug is
unable to cross cell membranes) elicited identical cAMP responses in HASM (Figure 2F). Cortisol and cortisol-BSA induced significant reductions in cADDis fluorescence within
4 minutes (as compared to vehicle) and reached a maximal response that was about half of that induced by a near-maximal
concentration of Fsk (1 µM). These data were consistent with
the idea that glucocorticoids activate a membrane-bound receptor via an outward-facing binding site to stimulate cAMP
production.

3.2 | Role of Gαs in mediating glucocorticoid
effects on production of cAMP
Since the stimulation of cAMP by glucocorticoids is rapid
and plasma membrane delimited, we hypothesized that the
response involves the direct activation of the stimulatory G
protein, Gαs. To this end, we used siRNA strategy to knockdown the expression of Gαs in HASM cells. HASM cells were
transfected with validated siRNA sequences specific for GNAS
or scrambled siRNA.35 As shown in Figure 3A, immunoblot

NUÑEZ et al.
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F I G U R E 3 Glucocorticoid stimulation of cAMP depends upon Gαs expression. A, HASM were transfected with siRNA specific for GNAS
or scrambled control for 48 hours and lysates analyzed by SDS-PAGE and immunoblotting simultaneously with antibodies specific for Gαs and
ß-actin. Image is representative of n = 3 experiments on separate donor cells. RNA sequencing revealed GNAS transcript was reduced 6.07 ± 0.35
fold (n = 6) following transfection with siRNA. B-E, cADDis sensor was expressed in control or Gαs-knockdown HASM using a recombinant
BacMam virus then responses to vehicle, forskolin (C), formoterol (C), budesonide (D), or fluticasone (E) were measured. Each point represents the
mean ± SEM of n = 4-5 donors. * denotes P < .05, ** denotes P < .01 of each time point

analysis indicated a reduction in expression of both the long and
short forms of Gαs in siRNA transfected HASM as compared
to scrambled control. We consistently observed a reduction in
the cADDis sensor expression levels following the transfection
procedure, which resulted in the maximal cADDis responses
being reduced by about 50% (comparing the response to 10 µM
Fsk in Figure 2 vs Figure 3). cAMP responses to vehicle or Fsk
(10 µM) were unaffected by Gαs knockdown, indicating that
adenylyl cyclase expression and total activity were unaffected
(Figure 3B). In contrast, cAMP responses to 100 nM formoterol
(a long-acting ß2-adrenoceptor agonist approved for the treatment of asthma) were significantly reduced in Gαs-knockdown
HASM as compared to control, consistent with ß-adrenoceptors
stimulating cAMP production via activation of Gαs (Figure 3C).
cAMP responses to budesonide (10 µM, Figure 3D) or fluticasone (10 µM, Figure 3E) were also significantly diminished in
cells with Gαs knockdown. Taken together, these results indicate that glucocorticoids activate a rapid, non-genomic signaling pathway that stimulates Gαs and the production of cAMP.

3.3 | Role of GPER in mediating
glucocorticoid effects on production of cAMP
Given that glucocorticoids act via an extracellular binding
site and depend upon Gαs, we hypothesize that a GPCR is
involved. The GPER is a known GPCR that is activated by
specific steroids and has been reported to couple to Gαs in
certain cells.36-39 1 and 10 µM estradiol stimulated small
cAMP responses that were not significantly different than
vehicle (Figure 4A). GPER mRNA is detected in a wide
array of cell types, including HEK-293, HFL-1, and HASM
cells (GEO accession numbers GSE128076, GSE73555, and
GSE52778). We examined budesonide cAMP responses in
cells preincubated with selective GPER antagonists to determine if glucocorticoids stimulated cAMP via activation
of GPER. In HASM cells, the addition of 1 µM G36 had
no effect on fluticasone stimulation of cAMP responses
(Figure 4B). Another GPER antagonist, G15 (1 µM), also
had no effect on fluticasone responses (Figure 4C). These

8
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F I G U R E 4 GPER antagonists do
not block glucocorticoid-stimulated cAMP
responses. Primary HASM cells were
incubated with recombinant BacMam virus
expressing the cADDis cAMP sensor. After
establishing baseline, fluorescence decay
was monitored for 30 minutes after addition
of drug. cADDis sensor fluorescent decay
curves elicited by 1 or 10 µM estradiol (A)
or 10 µM fluticasone (C). A different Y axis
scale is used on panel A to better visualize
these responses. Each point represents the
mean ± SEM of n = 5 donors and lines
represent the fit by one-phase decay nonlinear regression analysis. No significant
differences are seen comparing fluticasone
alone to either condition where a GPER
antagonist (G15 or G36) was included at
any time point using multiple t tests and
the Holm-Sidak method for correction of
multiple comparisons

results are consistent with the idea that the GPER is not involved in mediating the rapid cAMP signaling stimulated by
glucocorticoids.

3.4 | Transcriptional effects of glucocorticoid
non-genomic signaling through Gαs
Glucocorticoid effects on cells are attributed to their genomic
actions, so the role that this rapid, non-genomic signal plays
in regulating cell function is relatively under studied.5 To investigate the transcriptional effects of the non-genomic signaling through Gαs, we performed an RNA-Seq analysis from
HASM cells treated with 1 µM budesonide, comparing transcripts from control and Gαs-knockdown samples 24 hours
post-treatment. We used HASM cell lines isolated from six
different donors at the same passage. Each donor cell line was
subjected to four conditions: scrambled siRNA treated with
vehicle, scrambled siRNA treated with 1 µM budesonide,
GNAS siRNA treated with vehicle, GNAS siRNA treated
with 1 µM budesonide. We chose a 24-hour drug treatment
duration in order to capture the classical genomic effects of
glucocorticoids. We chose to use 1 µM budesonide since this
concentration elicited a sub-maximal cAMP response that
could be completely abolished by Gαs knockdown. In addition, this lower concentration is more consistent with other
studies of the genomic effects of glucocorticoid treatment.

With this approach, any observed differences in the budesonide transcriptomes between control and Gαs-knockdown
cells would reflect the role of the non-genomic glucocorticoid signaling. We performed quantitative analysis of the
transcripts that were altered by budesonide acting through
both genomic and non-genomic signaling (control) or acting
through only genomic signaling (Gαs knockdown).
We began our analysis with the hypothesis that the non-genomic transcriptional activities are due to signaling via Gαs.
Two novel budesonide signatures were generated using the
differential gene expression lists: (a) a 140-gene genomic and
non-genomic signature of budesonide effect in control cells, and
(b) a 121-gene genomic only signature of budesonide in Gαsknockdown cells (Figure 5; Supplemental Tables S1 and S2).
ASSIGN, a pathway analysis toolkit, was used to assess the
predictive ability of these gene-sets in determining budesonide
induced transcriptional activity. As an internal validation, we
used the signatures to predict budesonide activity in all 24
HASM samples using ASSIGN. Predictions show that both
signatures were able to correctly identify budesonide induced
transcriptional activity in all 24 HASM samples (Pearson's
correlation 0.9977; P < .0001; Supplemental Figure S4). To
validate these signatures further, we applied these two signatures to a previously published independent dataset of 34
HASM samples derived from asthma and non-asthma donors
with either control or budesonide treatment40 (GEO dataset
accession GSE94335). Since there are variation in budesonide

NUÑEZ et al.
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F I G U R E 5 The transcriptional activity due to budesonide treatment in HASM. A, 140 gene budesonide signature representing the
transcriptional activity (genomic + non-genomic) variation between control and budesonide treated HASM. B, 121 gene budesonide Gαs
knockdown signature showing the transcriptional activity (genomic only) variation between Gαs knockdown-control and budesonide-treated
HASM. For both (A) and (B), each row represents a gene, and each column represents a sample. The red cell color represents level of
overexpression and the blue cell color represents levels of low expression. Brighter the red, higher the gene expression and darker the blue, lower
the expression. C, Comparison of genes from each budesonide signatures show 94 genes were shared between budesonide (out of 140 genes) and
budesonide-Gαs knockdown (out of 121 genes) signatures. 48 genes unique to budesonide signature represent Gαs dependent activity

concentration and duration for the treatment conditions between the datasets (100 nM for 1 hour vs 1 µM for 24 hours of
budesonide treatment), we used ASSIGN’s background adaptive feature. Thus, the background gene expression differences
between our signature (training) and GSE94335 (test) samples
were adjusted to provide more accurate prediction. Despite the

slight difference in predicted genomic + non-genomic and genomic only budesonide activity, both signatures accurately estimated high budesonide activity in budesonide-treated HASMs
derived from both asthma and non-asthma donors (Pearson's
correlation 0.9995; P < .0001, Supplemental Table S1).40
This similarity in predicted budesonide activity validates the

10

|   

robustness of both types of budesonide signatures in capturing
transcriptional activity regardless of Gαs status 24 hours postbudesonide treatment. Although genes within each signature
are different, the ubiquitous effects of the canonical genomic
signaling pathway activated by budesonide, along with a large
number of genes in the signatures, maintains the robustness of
the predictive ability.
To evaluate the roles of these signature genes in known cellular processes, a gene set enrichment analysis was performed
with databases, particularly, Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathways and Gene Ontology (GO)
annotations.41 These databases provide curated gene-sets for
understanding the functions and utilities of biological systems,
cellular components, and molecular functions of a given test
gene-set. There was no significant enrichment of any KEGG
or GO gene-sets for the budesonide signature gene-lists after
adjusting the p-value for multiple comparisons. This implies
that these budesonide signatures present unique transcriptional
activity not represented by the gene-sets in these databases.
Next, we analyzed the overlapping genes from the two
budesonide signatures to evaluate the genomic and nongenomic interplay of these signature genes. There were 92 genes
shared between budesonide and budesonide Gαs-knockdown
signatures (Figure 5C). Forty-eight genes were unique to the
budesonide signature, indicating these genes (26 upregulated and 22 downregulated) are dependent on Gαs-dependent
budesonide transcriptional activity (Table 2,Supplemental
Figure S2). We then used an unsupervised hierarchical clustering method to investigate how the transcriptional activity
attributed to this non-genomic signature affected the HASM
without knowing the treatment conditions. Essentially, we
evaluated these 48 genes in their ability to differentiate the
treatment conditions. The hierarchical clustering clearly differentiates the two budesonide treatment conditions (Table 2,
Figure S2). The clustering also shows two distinct sub-clusters
that identify the non-genomic signature.
To find similar patterns of non-genomic transcriptional
activity in existing data sets, a gene expression query was performed using these 48 genes in the CMAP database. CMAP
is a publicly available independent dataset housing over one
million differential gene expression signatures. A CMAP
query is used to find similarities and dissimilarities across
the curated expression profiles of various perturbations, including compounds, overexpressions, and knockdowns.32 CS
is a quantitative score between a query gene-list and a perturbagen that ranges from −100 (opposing signature) to 100
(same signature). CS from a query with 48 Gαs-dependent
budesonide induced gene-list across the CMAP database was
the highest (98.97) for “GR agonist” among the 171 pharmacologic classes available in the CMAP database. CSs for
GR agonists including budesonide investigated in different cell lines including prostate (PC3), melanoma (A375),
lung (A549), and hepatocellular cancer (HA1E, HCC515)
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TABLE 2

List of 48 genes representing the non-genomic
budesonide transcriptional activity in HASM cells
Gene symbols

Gene name

ADARB1

adenosine deaminase, RNA-specific, B1

ADH1B

alcohol dehydrogenase 1B (class I), beta
polypeptide

ANGPTL1

angiopoietin-like 1

APBB2

amyloid beta (A4) precursor protein-binding, family B, member 2

ARID5A

AT rich interactive domain 5A (MRF1-like)

ARMC8

armadillo repeat containing 8

ARNTL

aryl hydrocarbon receptor nuclear translocator-like

CCDC102B

coiled-coil domain containing 102B

CCND3

cyclin D3

CHST7

carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7

CIART

Circadian Associated Repressor of Transcription

FADS1

fatty acid desaturase 1

FSTL3

follistatin-like 3 (secreted glycoprotein)

GAL

galanin prepropeptide

GPR1

G protein-coupled receptor 1

HMGA1

high mobility group AT-hook 1

IER5L

immediate early response 5-like

IL16

interleukin 16

LY96

lymphocyte antigen 96

MAP3K7CL

NAMAP3K7 C-Terminal Like

MEX3B

mex-3 homolog B (C. elegans)

MMD

monocyte to macrophage
differentiation-associated

NNMT

nicotinamide N-methyltransferase

NR1D1

nuclear receptor subfamily 1, group D, member 1

NR1D2

nuclear receptor subfamily 1, group D, member 2

NRG1

neuregulin 1

PDE5A

phosphodiesterase 5A, cGMP-specific

PDLIM1

PDZ and LIM domain 1

PER1

period homolog 1 (Drosophila)

PKDCC

protein kinase domain containing, cytoplasmic
homolog (mouse)

PLA2G4A

phospholipase A2, group IVA (cytosolic,
calcium-dependent)

PLXNA2

plexin A2

PRRX1

paired related homeobox 1

PTPRG

protein tyrosine phosphatase, receptor type, G

PTX3

pentraxin 3, long

RAB7B

RAB7B, member RAS oncogene family

RGMB

RGM domain family, member B

SEMA3A

sema domain, immunoglobulin domain (Ig), short
basic domain, secreted, (semaphorin) 3A
(Continues)
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TABLE 2

(Continued)

Gene symbols

Gene name

SH3PXD2B

SH3 and PX domains 2B

SHISAL1

Shisa Like 1

SLC19A2

solute carrier family 19 (thiamine transporter),
member 2

SQOR

Sulfide Quinone Oxidoreductase

SSX2IP

synovial sarcoma, X breakpoint 2 interacting
protein

STOM

stomatin

SYNJ2

synaptojanin 2

TEF

thyrotrophic embryonic factor

TMEM158

transmembrane protein 158 (gene/pseudogene)

ZBTB16

zinc finger and BTB domain containing 16

show high similarity (CSs>90) (Supplemental Figure S3,
Table S2). This high similarity across various cell lines
and glucocorticoid agonists indicates that the non-genomic
budesonide signature, as represented by these 48 genes, extends beyond HASM and is significantly associated with the
GR agonists including, but not limited to, budesonide.
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D IS C U SSION

A number of glucocorticoids cause rapid increases in cAMP
levels in multiple cell types (Figures 1 and 2). These responses
appear to be mediated by a plasma membrane-associated receptor with an outward facing binding site since albuminconjugated cortisol, which can't cross the plasma membrane,
retains activity (Figure 2F). The increase in cAMP levels requires stimulation of Gαs, as knockdown of GNAS via siRNA
drastically reduces cAMP signaling by glucocorticoids.
Since our cAMP assays are performed in the absence of PDE
inhibitors there is a possibility that glucocorticoids could
work via inhibition of PDE activity. However, inclusion of a
broad spectrum PDE inhibitor did not impinge upon fluticasone responses, implying that the glucocorticoid works independently of PDE inhibition. Glucocorticoids can also inhibit
uptake of ß-adrenergic receptor (ßAR) agonists by cells42 but
our assays are performed in cultured cells with no other drugs
or serum present. In these conditions, glucocorticoids would
not increase cAMP within seconds via inhibition of uptake of
other drugs, even if the cells were producing autocrine-acting
agonists. Glucocorticoids are also known to increase expression of ßAR43 but this occurs via genomic action so also can't
explain our observations.
Based on these findings we speculate that these glucocorticoids activate a GPCR of unknown identity. This mechanism appears to be highly conserved through evolution since
both insect and amphibian genomes appear to contain GPCRs
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that respond to glucocorticoids.9,44 The canonical nuclear GR
appears to be dispensable for the response as its knockdown
via siRNA had little effect on these responses.34 RU-486, a
progesterone and GR antagonist, blocks the non-genomic
signaling but this chemical likely has the structural elements needed to antagonize glucocorticoid action at non-GR
binding sites.34 RU-486 can also stimulate GR responses so
this chemical can act as both an antagonist and an agonist
of GR.45,46 GR has been shown to exist in the plasma membrane of various cells.17 Plasma membrane GR could directly
activate Gαs or may do so via transactivation of a GPCR.
However, the concentrations required to activate cAMP signaling are much higher than those that activate genomic signaling, implying that these occur via different binding sites. It
does not appear that glucocorticoids work through binding to
GPER since two different antagonists had no effect on glucocorticoid cAMP responses (Figure 4). More work is needed
to thoroughly understand the receptor mechanism involved in
glucocorticoid stimulation of cAMP.
A number of investigators have reported rapid actions of
glucocorticoids in various cells and tissues. These effects
include modulation of basal and stimulated intracellular calcium levels, increases in reactive oxygen species and reactive
nitrogen species, increased inflammatory and apoptotic pathways and reduced skeletal and smooth muscle tone (recently
reviewed in 5). Gαs-cAMP signaling has numerous and diverse
effects in all cells so many of these prior observations of
rapid glucocorticoid signaling may be mediated via increased
cAMP. Efforts to understand the non-genomic effects of
glucocorticoids have focused on using the membraneimpermeable cortisol-BSA conjugate.17,18 However, this
agent is a weak activator of cAMP signaling (Figure 2F) so
this is not an optimal approach. Gαs knockdown is a more
specific and effective intervention that will be a more powerful means for understanding this non-genomic signaling.
This approach will be useful for understanding the divergent
actions of glucocorticoids in other cells and tissues (at least
until the membrane receptor involved is identified).
Other work demonstrates the physiological relevance of
this non-genomic signaling by glucocorticoids. We demonstrate that budesonide-stimulated cAMP augments formoterolinduced bronchodilation in human small airways when
combined with formoterol, a long-acting ßAR agonist.34 It
is interesting to note that in the present study the glucocorticoids most efficacious at stimulating cAMP production were
budesonide and fluticasone, two drugs developed for inhaled
use in asthma. The clinical utility of these inhaled glucocorticoids is clearly enhanced by this unappreciated non-genomic
signaling that enhances bronchodilation. While success of
these important drugs may have been aided by this additional
activity, a complete understanding of this alternate signaling paradigm may inform future development of new drugs.
Can drugs be designed with different mixtures of genomic
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and non-genomic actions for specific clinical applications?
Some side effects of glucocorticoids may be dependent on
one signaling pathway or another, allowing improved drug
design. Finally, a novel membrane receptor capable of augmenting bronchodilation in small airways could provide a
much-needed alternative drug target to existing ßAR agonists, which suffer from issues with tachyphylaxis and potential maladaptive responses after long-term use.
Confirmation that glucocorticoids act via both rapid,
non-genomic, and canonical genomic signaling mechanisms
led us to ask what the role of each might be in context of the
known effects of these drugs on the gene transcription. We hypothesized that the cAMP signal serves as a primer to subsequent genomic effects, shaping the size, and/or direction of the
transcription of particular genes. Using RNA-seq and comparing the budesonide treatment transcriptomes from control cells
and cells with Gαs knockdown allowed identification of the effects of both the genomic and non-genomic signals. Comparing
our data to existing data sets demonstrate that the gene expression changes we observe are highly reproducible across other
cell types and other glucocorticoids. We identified a panel of
140 differentially expressed genes that characterize the effects
of budesonide in HASM. Of these, 94 genes were shared between the control and Gαs knockdown conditions and 48 were
unique to the control. These 48 genes (Table 2) depend upon
the non-genomic cAMP signal for their differential expression
since they were not significantly altered by budesonide treatment in cells lacking Gαs. Thus, one-third of the genes altered
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by budesonide treatment depended upon the non-genomic
signal in some way. These results show the importance of this
alternate signaling mechanism and force a rethinking of how
glucocorticoids act to alter cell function. We propose that this
non-genomic site of action is not an off-target effect, but rather
an integral part of canonical glucocorticoid action.
Our study does have some limitations that require further research. In particular, we chose a 24 hours time point
to study the transcriptional effects of budesonide in order
to capture the classical genomic effects. A rapid increase in
cAMP upon adding glucocorticoid to HASMs suggests that
the non-genomic signaling could begin to alter the transcriptional activity soon after (within an hour or two) glucocorticoid application. Therefore, the transcriptional activity we
observe at the 24 hours time point may be too late to capture
the full effect of the non-genomic signaling events. Additional
studies are needed to capture RNA-Seq datapoints from early
glucocorticoid treatments to better understand non-genomic
activity attributed to glucocorticoids. Even with this limitation, our data makes clear that the non-genomic signaling via
Gαs and cAMP contributes substantially to the regulation of
certain glucocorticoid-responsive genes. We imagine that the
non-genomic signal integrates with the genomic signal via
the convergence of transcription factors regulated by cAMP,
including but not limited to CREB, with classical GRE at
the promotor of certain genes (Figure 6). More research is
needed to understand how these very different signaling modalities integrate at the level of the gene transcription.

F I G U R E 6 Schematic diagram of
proposed signaling by a putative membrane
glucocorticoid receptor (mGR). We
propose two signaling pathways mediated
by glucocorticoids, the canonical cytosolic
GRα receptor mediating direct genomic
effects via GRE and a second, non-genomic
activation of Gαs and cAMP signaling
(illustrated here as signaling via CREB
for simplicity, but other transcription
factors are likely involved). The latter
can have both rapid effects and effects
that contribute to the genomic actions of
glucocorticoids
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Our study is also limited to a few cell types (just HASM in
the case of RNA-seq) so broad conclusions about the relevance
non-genomic cAMP signaling by glucocorticoids won't be appreciated until other cell types can be studied. However, our
analysis of the 48 gene non-genomic signature in the existing
gene expression datasets indicate that many cell types contain
this signature. It will be of particular importance to understand
how immune cells, major targets of glucocorticoid therapy,
respond in terms of both genomic, and non-genomic signaling. The concentrations required for glucocorticoids to induce
cAMP signaling are higher than those associated with activation of nuclear glucocorticoid receptors. While this highlights
that a different receptor may be involved, one might question
the clinical relevance of the glucocorticoid concentrations we
use. While local tissue concentrations of budesonide following
inhalation dosing are difficult to determine, plasma concentrations of glucocorticoid following oral dosing of 80 mg in
humans reaches peaks of nearly 4 µM.47 Thus, the responses
we observe are relevant to therapeutic uses of glucocorticoids.
Our study identifies a rapid, non-genomic signaling
mechanism by glucocorticoids that contributes to the known
gene expression changes induced by these drugs. By acting
on a membrane receptor and stimulating Gαs, glucocorticoids
increase the cAMP levels in cells within seconds. We hypothesize that these signals get integrated into the networks that
alter the expression of many genes along with the canonical
genomic signaling by nuclear GR. This non-genomic signal
can also contribute to rapid effects such a smooth muscle relaxation and likely many others. These findings help explain
the clinical utility of inhaled glucocorticoids on an acute
basis but also provide a specific mechanism that can be leveraged for the development of future glucocorticoid analogs.
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Supplemental Figure 1: Venn diagram showing the overlap of differentially expressed genes
due to budesonide 24-hour treatment in (1) control, (2) Gas knockdown (kd) HASM, and (3)
dexamethasone 18-hour treatment in control HASM published by Himes et al. 2014.

Supplemental Figure 2: Unsupervised Hierarchical clustering of log2(TPM) gene expression of
48 genes unique in budesonide signature compared to Gas-knockdown budesonide signature
captures budesonide-specific transcriptional activity in HASM. Dendrograms represent the
hierarchical clustering based on the Euclidean distance between two gene expression values or
two samples. 26 of the 48 genes are overexpressed with budesonide treatment. Darker red
indicates higher expression, and darker blue indicates lower expression.

Supplemental Figure 3: Top 10 ranked connectivity scores, quantitative scores between a
query gene-list and a perturbagen in nine cell lines. Members of glucocorticoid agonists had
high connectivity score when 48 genes unique to budesonide’s Gas-dependent gene expression
were queried for similarities and dissimilarities against more than a million gene expression
signatures in ConnectivityMap (CMap), a publicly available database.

Supplemental Figure 4: Predicted budesonide activities using both budesonide (genomic +
non-genomic) and budesonide Gas knockdown (genomic only) signatures were significantly
correlated (r=0.9977, p-value < 0.0001).

Supplemental Table 1: Predicted budesonide activity using budesonide (genomic + nongenomic) and budesonide Gas knockdown (genomic only) signatures in 34 Human Airway
Smooth Muscle samples from Kan et al.40
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budesonide
budesonide
budesonide
vehicle
vehicle
vehicle
vehicle
vehicle
vehicle
vehicle
vehicle
vehicle
vehicle
vehicle
vehicle
vehicle
vehicle
vehicle
vehicle
vehicle

Budesonide activity
signature (genomic
+ non-genomic)
0.98
0.86
0.97
0.97
0.96
0.98
0.97
0.98
0.98
0.97
0.98
0.98
0.98
0.98
0.94
0.99
0.98
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Budesonide
activity signature
(genomic only)
0.96
0.94
0.98
0.99
0.96
0.99
0.94
0.99
0.98
0.96
0.98
0.98
0.98
0.99
0.97
0.99
0.98
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Supplemental Table 2: Ranked connectivity scores (CS) for highly similar (>95) and dissimilar
(<-95) gene expression against more than 1.7 million perturbation samples in CMAP database
filtered for perturbation class and perturbation class members.
Connectivity
Score (CS)
98.97
98.84
98.77
98.59
98.56
98.13
98.06
97.96
97.65
97.59

Name

Description

Glucocorticoid receptor agonist
dexamethasone
fluocinolone
fluorometholone
tacrolimus
halometasone
mometasone
clobetasol
fluocinonide
betamethasone

Glucocorticoid receptor agonist
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist
Calcineurin inhibitor
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist

97.57
97.42

methylprednisolone
fludroxycortide

Glucocorticoid receptor agonist
Glucocorticoid receptor agonist

97.32
97.29

alclometasone
megestrol

Glucocorticoid receptor agonist
progesterone receptor agonist

97.24
97.08

beclometasone
fluticasone

Glucocorticoid receptor agonist
Glucocorticoid receptor agonist

97.08
97.04
96.97
96.97
96.9
96.79
96.62
96.62

L-690330
flumetasone
hydrocortisone
RHO-kinase-inhibitor-III[rockout]
desoximetasone
triamcinolone
tropisetron
hydrocortisone

Inositol monophosphatase inhibitor
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist
Rho associated kinase inhibitor
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist
Serotonin receptor antagonist
Glucocorticoid receptor agonist

96.58
96.09
95.77
95.55

hydrocortisone
fluticasone
budesonide
halcinonide

Glucocorticoid receptor agonist
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist

95.14
-96.81

rimexolone
PJ-34

Glucocorticoid receptor agonist
PARP inhibitor

